Idiopathic Thrombocytopenic Therapeutic and Drugs Pipeline Review H2

WiseGuyReports.com adds Exclusive Research on “Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Review, H2 2016” reports to its database.

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Review, H2 2016

 

The report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects.

 

Get Sample Report @ https://www.wiseguyreports.com/sample-request/649789-idiopathic-thrombocytopenic-purpura-immune-review-h2-2016    

 

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

 

Scope

– The report provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

– The report reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics and enlists all their major and minor projects

– The report assesses Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

 

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview 9

Therapeutics Development 10

Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Overview 10

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Therapeutics under Development by Companies 11

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Products under Development by Companies 16

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Companies Involved in Therapeutics Development 18

3SBio Inc. 18

AkaRx Inc 19

Amgen Inc. 20

arGEN-X BV 21

Boehringer Ingelheim GmbH 22

Bristol-Myers Squibb Company 23

Genosco 24

Hansa Medical AB 25

Immunomedics, Inc. 26

Intas Pharmaceuticals Ltd. 27

Jiangsu Hengrui Medicine Co., Ltd. 28

Merck & Co., Inc. 29

Momenta Pharmaceuticals, Inc. 30

Novartis AG 31

Pfizer Inc. 32

PhytoHealth Corporation 33

Protalex, Inc. 34

Rigel Pharmaceuticals, Inc. 35

Shire Plc 36

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Therapeutics Assessment 37

Assessment by Monotherapy Products 37

Assessment by Target 38

Assessment by Mechanism of Action 40

Assessment by Route of Administration 42

Assessment by Molecule Type 44

Drug Profiles 46

Antibody for Autoimmune Disorders and Inflammation – Drug Profile 46

…Continued

 

Access Report @ https://www.wiseguyreports.com/reports/649789-idiopathic-thrombocytopenic-purpura-immune-review-h2-2016

 

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: https://twitter.com/WiseGuyReports

Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts    

Media Contact
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: sales@wiseguyreports.com
Phone: +1 646 845 9349, +44 208 133 9349
City: New York City
State: NY
Country: United States
Website: www.wiseguyreports.com